Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Global X Defense Tech ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B), while Global X Defense Tech ETF trades at $59.87 (market cap $6.29B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4× Global X Defense Tech ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and Global X Defense Tech ETF for 44 Days on average.
| RPRX | SHLD | |
|---|---|---|
Market Cap | $25.27B | $6.29B |
Volume | 3,671,183 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $63.96 | $78.02 |
52-Week Low | $35.44 | $58.20 |
Typical Hold Time | 1 Days | 44 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SHLD, the Global X Defense Tech ETF, trades at $59.19, up 0.77% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower, while RSI levels suggest potential oversold conditions. The fund focuses on defense technology and cybersecurity, benefiting from rising global defense budgets, as highlighted by recent institutional buying and positive news flow on European rearmament efforts.
The outlook for SHLD is supported by geopolitical tailwinds and institutional accumulation, but near-term technical weakness and reliance on defense spending cycles pose risks. Investors gain exposure to innovative defense firms, yet must monitor budget approvals and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
